Agios Pharmaceuticals
Update in progressAGIO (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Agios Pharmaceuticals is a Cambridge, Massachusetts–based biopharmaceutical company focused on medicines that target cellular metabolism. Its lead product, PYRUKYND (mitapivat), activates pyruvate kinase and treats adults with PK deficiency–related hemolytic anemia; it is in Phase 3 for sickle cell disease and studied in pediatric PK deficiency. It also develops AQVESME for alpha- or beta-thalassemia, and programs including tebapivat, AG-181, and AG-236.
Company score
- Sentiment
- 0.37
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.16
- Governance
- 0.10
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.07
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.22
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEOMr. Brian M. Goff M.B.A.
- Founded2007
- Employees539
- Websitewww.agios.com
Identifiers
- ISINUS00847X1046
- FIGIBBG000QY4ZD0
- LEI529900ONJHY8EOGYT555
- CUSIP00847X104
- CIK0001439222